EI
NBIX icon

Ethic Inc’s Neurocrine Biosciences NBIX Stock Holding History

Ethic Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,545
Closed -$272K – 1273
2025
Q1 		$272K Sell
2,545
-1,647
-39% -$209K 0.01% 975
2024
Q4 		$572K Buy
4,192
+1,073
+34% +$133K 0.01% 757
2024
Q3 		$430K Buy
3,119
+207
+7% +$28.4K 0.01% 797
2024
Q2 		$401K Sell
2,912
-207
-7% -$28.4K 0.01% 814
2024
Q1 		$430K Sell
3,119
-1,337
-30% -$183K 0.01% 796
2023
Q4 		$587K Buy
4,456
+811
+22% +$93.4K 0.02% 688
2023
Q3 		$410K Buy
+3,645
New +$384K 0.01% 737

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ethic Inc's NBIX Position: Q2 2025 in Review

Ethic Inc sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 2,545 shares — an estimated $272K sold.

Ethic Inc first reported a position in NBIX in Q3 2023 and held it in 7 quarters. The position peaked at $587K in Q4 2023. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Ethic Inc reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Ethic Inc sold 2,545 Neurocrine Biosciences shares in Q2 2025, an estimated $272K.
  • Ethic Inc first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 7 quarters.
  • Ethic Inc's Neurocrine Biosciences position peaked at $587K in Q4 2023.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Ethic Inc's 13F filing for Q2 2025, filed 30 Jul 2025.